PDCD1 and neoplasm: Targeting MDSCs with sunitinib improved T-cell-mediated anti-tumor immunity by promoting infiltration, reducing T-cell exhaustion, and upregulating PD-L1 expression, which sensitized the tumors to anti-PD1 therapy [44].